Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria

Bernd Höppe, Craig B. Langman, David McDougall et al.|Kidney International|2021

Cited by 90